Korean J Dermatol.  1987 Aug;25(4):460-466.

A Clinical Evaluation of the Effects of Combination Photochemotherapy in the Treatment of Psoriasis with Etretinate and PUVA

Abstract

RePUVA therapy is the combination of an oral aromatic retinoid(etretinate) with oral photochemotherapy (PUVA) for the treatment of psoriasis. This combination therapy has the advantage of faster clearance with fewer side effects. Twenty three ambulatory psoriasis patients received RePUVA treatment. Etretinate was administered in a dosage of approxirnately 0.75 mg/kg body weight for 2 weeks and discontinued. One week after discontinuance of etretinate, PUVA therapy was begun. Complete clearance occured in 96% of the patients with an average of 9.5+4 irradiations and an accumulated ultraviolet A (UVA) dose of 67.5+42 J/cm. The primary side effects were dry rnucous membranes and mild cheilitis. Laboratory findings revealed no significant abnormalities before or after etretinate treatment.

Keyword

Psoriasis; Etretinate; PUVA; RePUVA

MeSH Terms

Acitretin*
Body Weight
Cheilitis
Etretinate*
Humans
Membranes
Photochemotherapy*
Psoriasis*
PUVA Therapy
Acitretin
Etretinate
Full Text Links
  • KJD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr